Development of Customizable Implementation Guides to Support Clinical Adoption of Pharmacogenomics: Experiences of the Implementing GeNomics In pracTicE (IGNITE) Network - PubMed

Development of Customizable Implementation Guides to Support Clinical Adoption of Pharmacogenomics: Experiences of the Implementing GeNomics In pracTicE (IGNITE) Network - PubMed

Development of Customizable Implementation Guides to Support Clinical Adoption of Pharmacogenomics: Experiences of the Implementing GeNomics In pracTicE (IGNITE) Network

Benjamin Q Duong 1, Meghan J Arwood 2, J Kevin Hicks 3, Amber L Beitelshees 4, Francesco Franchi 5, John T Houder 2, Nita A Limdi 6, Kelsey J Cook 7 8, Aniwaa Owusu Obeng 9, Natasha Petry 10, Sony Tuteja 11, Amanda R Elsey 2, Larisa H Cavallari 2, Kristin Wiisanen 2, IGNITE Network

Affiliations 

• PMID: 32765043
 
• PMCID: PMC7373415
 
• DOI: 10.2147/PGPM.S241599

Free PMC article

Abstract

Introduction: Clinical adoption of genomic medicine has lagged behind the pace of scientific discovery. Practice-based resources can help overcome implementation challenges.

Methods: In 2015, the IGNITE (Implementing GeNomics In pracTicE) Network created an online genomic medicine implementation resource toolbox that was expanded in 2017 to incorporate the ability for users to create targeted implementation guides. This expansion was led by a multidisciplinary team that developed an evidence-based, structured framework for the guides, oversaw the technical process/build, and pilot tested the first guide, CYP2C19-Clopidogrel Testing Implementation.

Results: Sixty-five resources were collected from 12 institutions and categorized according to a seven-step implementation framework for the pilot CYP2C19-Clopidogrel Testing Implementation Guide. Five months after its launch, 96 CYP2C19-Clopidogrel Testing Implementation Guides had been created. Eighty percent of the resources most frequently selected by users were created by IGNITE to fill an identified resource gap. Resources most often included in guides were from the test reimbursement (22%), Implementation support gathering (22%), EHR integration (17%), and genetic testing workflow steps (17%).

Conclusion: Lessons learned from this implementation guide development process provide insight for prioritizing development of future resources and support the value of collaborative efforts to create resources for genomic medicine implementation.

Keywords: CYP2C19; CYP2D6; clinical pharmacogenomics; clopidogrel; implementation; personalized medicine; pharmacogenomics; precision medicine.

© 2020 Duong et al.

Conflict of interest statement

Authors declare the following potential competing interests: NAL serves as a consultant for Admera Health; JKH receives clinical trial support from OneOme, LLC, reports personal fees from Novartis and grants from ASHP, and serves as a consultant for Quest Diagnostics; ALB and NP report grants from NIH; FF receives consulting fee or honoraria from Astra Zeneca and Sanofi. KW reports grants from National Human Genome Research Institute and Clinical Translational Science Award Program. The authors report no other conflicts of interest in this work.